+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Results of a Phase Ii Trial of Tumor Lysate-pulsed Dendritic Cell Vaccination for Malignant Glioma



Results of a Phase Ii Trial of Tumor Lysate-pulsed Dendritic Cell Vaccination for Malignant Glioma



Neurosurgery 57(2): 409-410




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 067462021

Download citation: RISBibTeXText

DOI: 10.1093/neurosurgery/57.2.409b


Related references

Vaccination with tumor cell lysate-pulsed dendritic cells augments the effect of IFN-beta gene therapy for malignant glioma in an experimental mouse intracranial glioma. International Journal of Cancer 111(5): 777-782, 2004

Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. British Journal of Cancer 89(7): 1172-1179, 2003

Enhancement of anti-tumor immunity specific to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12. Cancer Immunology ImmunoTherapy 55(11): 1309-1319, 2006

Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Research 64(14): 4973-4979, 2004

Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. CytoTherapy 12(6): 721-734, 2010

Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients. Journal of ImmunoTherapy 36(2): 152-157, 2013

Vaccination therapy of pancreatic carcinoma patients with autologous, tumor-lysate pulsed dendritic cells: Results of a phase II study. Journal of Clinical Oncology 26(15_Suppl): 3069-3069, 2016

Preliminary results of a phase II-study: Vaccination therapy of pancreatic carcinoma patients with autologous, tumor lysate pulsed dendritic cells. Journal of Clinical Oncology 24(18_Suppl): 14102-14102, 2016

Characterization of CD34+ progenitor-derived dendritic cells pulsed with tumor cell lysate for a vaccination strategy in children with malignant solid tumors and a poor prognosis. Klinische Padiatrie 216(3): 176-182, 2004

Improved therapeutic efficacy using vaccination with glioma lysate-pulsed dendritic cells combined with IP-10 in murine glioma. Vaccine 27(44): 6210-6216, 2009

Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. Journal of ImmunoTherapy 28(5): 496-504, 2005

Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model. International Journal of Cancer 122(8): 1794-1802, 2008

Dipg-08. Phase Ib Immunotherapy Clinical Trial With The Use Of Autologous Dendritic Cells Pulsed With An Allogenic Tumoral Cell Lines Lysate In Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (Dipg). Neuro-Oncology 19(Suppl_4): iv6, 2017

A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clinical Cancer Research 8(4): 1021-1032, 2002

Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2. Melanoma Research 13(5): 521-530, 2003